Tuesday, December 23, 2014
Home
Betaxon

Betaxon


View the Eye Diseases and Conditions Slideshow Pictures

Betaxon Drug Description


BETAXON
(levobetaxolol hydrochloride) Ophthalmic Suspension 0.5%
Sterile Topical Ophthalmic Drops

DRUG DESCRIPTION

BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% contains levobetaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile resin suspension formulation. Levobetaxolol hydrochloride is a white, crystalline powder with a molecular weight of 343.89. The specific rotation is:

[α]25°C/589nm -19.67°(c=20 mg/mL; methanol)

The chemical structure is:

 

BETAXON (levobetaxolol hydrochloride) Structural Formula Illustration

Empirical Formula: C18H29NO3•HCl

Chemical Name: (S)-1-[p-[2-(cyclopropylemethoxy)ethyl]phenoxy]3-(isopropylamino)-2-propanol hydrochloride.

Each mL of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% contains: Active: levobetaxolol HCl 5.6 mg equivalent to 5.0 mg of levobetaxolol free base. Preservative: benzalkonium chloride 0.01%. Inactives: mannitol, poly(styrene-divinyl benzene) sulfonic acid, Carbomer 974P, boric acid, N-lauroylsarcosine, edetate disodium, hydrochloric acid or tromethamine (to adjust pH) and purified water. It has a pH of 5.5 to 7.5 and an osmolality of 260 to 340 mOsm per kg.

 

What are the possible side effects of levobetaxolol ophthalmic (Betaxon)?

If you experience any of the following serious side effects, stop using levobetaxolol ophthalmic and seek emergency medical attention or contact your doctor immediately:

  • an allergic reaction (swelling of the lips, face, or tongue; difficulty breathing; closing of the throat; or hives);
  • an asthma attack (shortness of breath, wheezing); or
  • irregular, fast, or slow heartbeats or changes in blood pressure.

Other, less serious side effects may be more likely to occur. Continue to use...

 

Betaxon


Betaxon Indications & Dosage


INDICATIONS

BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% is indicated for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

Recommended Dosing

The recommended dose is one drop of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% in the affected eye(s) twice daily. In some patients, the intraocular pressure lowering responses to BETAXON (levobetaxolol hydrochloride ophthalmic suspension) TM Ophthalmic Suspension may require a few weeks to stabilize. As with any new medication, careful monitoring of patients is advised. The concomitant use of two topical beta-adrenergic agents is not recommended.

HOW SUPPLIED

Dosage Forms And Strengths

Bottle filled with 5, 10, and 15 mL of 0.5% sterile ophthalmic suspension.

Storage And Handling

BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% is supplied as follows: 5, 10 and 15 mL in a clear LDPE plastic ophthalmic DROP-TAINER® dispenser and a yellow polypropylene screw cap.

5 mL: NDC 0065-0239-05
10 mL: NDC 0065-0239-10
15 mL: NDC 0065-0239-15

Storage

Store upright at 39°to 77°F (4°to 25°C).

Protect from Light.

Shake well before using.

Alcon Laboratories, Inc., Fort Worth, Texas 76134 USA

 

Betaxon


Betaxon Side Effects & Drug Interactions


SIDE EFFECTS

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Ocular: In clinical trials, the most frequent event associated with the use of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension 0.5% has been transient ocular discomfort upon instillation (11%). Transient blurred vision has been reported in approximately 2% of patients. Other ocular events have been reported in less than 2% of patients and include: cataracts, and vitreous disorders.

Systemic: Systemic reactions following administration of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension 0.5% and other topical ocular formations of betaxolol have been at an incidence of less than 2%. These include:

Cardiovascular: Bradycardia, heart block, hypertension, hypotension, tachycardia, and vascular anomaly.

Central Nervous System: Anxiety, dizziness, hypertonia, and vertigo.

Digestive: Constipation and dyspepsia.

Endocrine: Diabetes and hypothyroidism.

Metabolic and Nutritional Disorders: Gout, hypercholesteremia, and hyperlipidemia.

Musculoskeletal: Arthritis and tendonitis.

Pulmonary: Pulmonary distress characterized by bronchitis, dyspnea, pharyngitis, pneumonia, rhinitis, and sinusitis.

Skin and Appendages: Alopecia, dermatitis, and psoriasis.

Special Senses: Ear pain, otitis media, taste perversion, and tinnitus.

Urogenital: Breast abscess and cystitis.

Other: Accidental injury, headache, and infection.

In a three-month, multi-center, double-masked, active-controlled trial in pediatric patients, the adverse event profile of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension was comparable to that seen in adult and elderly patients.

DRUG INTERACTIONS

Oral Beta-Adrenergic Receptor Blocking Agents

Patients who are receiving a beta-adrenergic blocking agent orally and BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta blockade.

Catecholamine-Depleting Drugs

Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or bradycardia.

Concomitant Adrenergic Psychotropic Drugs

Levobetaxolol is an adrenergic blocking agent; therefore, caution should be exercised in patients using concomitant adrenergic psychotropic drugs.

Betaxon


Betaxon Warnings & Precautions


WARNINGS

Included as part of the PRECAUTIONS section.

PRECAUTIONS

General

Topically applied beta-adrenergic blocking agents may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported with topical application of beta-adrenergic blocking agents.

Cardiac Failure

BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension has been shown to have a minor effect on heart rate and blood pressure in clinical studies. Caution should be used in treating patients with a history of cardiac failure or heart block. Treatment with BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension should be discontinued at the first signs of cardiac failure.

Bronchospasm and Obstructive Pulmonary Disease

Caution should be exercised in the treatment of glaucoma patients with excessive restriction of pulmonary function. There have been reports of asthmatic attacks and pulmonary distress during betaxolol treatment. Although rechallenges of some such patients with ophthalmic betaxolol has not adversely affected pulmonary function test results, the possibility of adverse pulmonary effects in patients sensitive to beta-blockers cannot be ruled out.

Thyrotoxicosis

Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents, which might precipitate a thyroid storm.

Muscle Weakness

Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis and generalized weakness).

Surgical Anesthesia

Consideration should be given to the gradual withdrawal of beta-adrenergic blocking agents prior to general anesthesia because of the reduced ability of the heart to respond to beta-adrenergically mediated sympathetic reflex stimuli.

Diabetes Mellitus

Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

Atopy/Anaphylaxis

While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

Angle-Closure Glaucoma

In patients with angle-closure glaucoma, the immediate treatment objective is to reopen the angle by constriction of the pupil with a miotic agent. Racemic betaxolol has little or no effect on the pupil. It is expected that levobetaxolol will also have little or no effect on the pupil. When BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension is used to reduce elevated intraocular pressure in angle-closure glaucoma, it should be used with a miotic and not alone.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

In lifetime studies in mice at oral doses of 6, 20 and 60 mg/kg/day and in rats at oral doses of 3, 12 and 48 mg/kg/day, betaxolol HCl demonstrated no carcinogenic effect. Levobetaxolol was not mutagenic in the Ames assay, chromosomal aberration, mouse lymphoma, and cell transformation assays in vitro. Levobetaxolol demonstrated potential mutagenicity in the sister chromatid exchange assay in Chinese Hamster Ovarian cell in vitro in the presence of metabolic activation systems.

Use In Specific Populations

Pregnancy

Pregnancy Category C

Reproduction, teratology, and peri- and postnatal studies have been conducted with orally administered betaxolol HCl and levobetaxolol HCl in rats and rabbits. There was evidence of drug related postimplantation loss in rabbits with levobetaxolol HCl at 12 mg/kg/day and sternebrae malformations at 4 mg/kg/day. No other adverse effects on reproduction were noted at subtoxic dose levels.

There are no adequate and well-controlled studies in pregnant women. BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension is administered to nursing women.

Pediatric Use

The safety and IOP-lowering effects of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension have been demonstrated in pediatric patients in a three-month controlled trial.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

 

Betaxon


Betaxon Overdosage & Contraindications


OVERDOSE

No information provided.

CONTRAINDICATIONS

BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with overt cardiac failure.

 

Betaxon


 

Betaxon Clinical Pharmacology


CLINICAL PHARMACOLOGY

Mechanism of Action

Levobetaxolol is a cardioselective (beta-1adrenergic) receptor blocking agent that does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Animal studies suggest levobetaxolol (S-isomer) is the more active enantiomer of betaxolol (racemate).

When instilled in the eye, BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension has the action of reducing elevated intraocular pressure. Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Since racemic betaxolol and other beta-adrenergic antagonists have been shown to reduce intraocular pressure by a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry, it is assumed that the mechanism of action of levobetaxolol is similar.

Pharmacodynamics

The intraocular pressure lowering effect of racemic betaxolol can generally be noted within 30 minutes and the maximal effect can usually be detected two hours after topical administration. It is assumed that the intraocular pressure lowering time profile of levobetaxolol is similar. A single dose provides approximately a 12-hour reduction in intraocular pressure.

Pharmacokinetics

BETAXON™ Ophthalmic Suspension 0.5% (levobetaxolol hydrochloride ophthalmic suspension) was dosed topically for 7 days to steady-state in 20 normal volunteers. An average maximal levobetaxolol plasma concentration (Cmax) of 0.5 ± 0.14 ng/mL was reached about three hours after the last dose. The mean half-life of levobetaxolol was approximately 20 hours.

Clinical Studies

In two well-controlled clinical studies in which a total of 356 patients were dosed for three months, BETAXON (levobetaxolol hydrochloride ophthalmic suspension) &™ Ophthalmic Suspension produced clinically relevant reductions in IOP at a follow-up visit. At 8 AM after nighttime dosing (trough), IOP was reduced from baseline approximately 4 to 5 mmHg (16% to 21%). At 10AM, two hours after dosing (peak), IOP was reduced from baseline approximately 5 to 6 mmHg (20% to 23%).

In comparisons between BETAXON (levobetaxolol hydrochloride ophthalmic suspension) TM Ophthalmic Suspension 0.5% and non-cardioselective beta blockers in reactive airway subjects, BETAXON (levobetaxolol hydrochloride ophthalmic suspension) TM Ophthalmic Suspension is expected to demonstrate less effect on pulmonary function [FEV1 and Forced Vital Capacity (FVC)].

The cardiovascular effects of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension 0.5% and betaxolol ophthalmic solution 1% were compared in double-masked, crossover studies to timolol maleate ophthalmic solution 0.5%. Levobetaxolol and betaxolol were shown during exercise to have significantly less effect on heart rate and systolic blood pressure than timolol maleate.

 

Betaxon


Betaxon Medication Guide


PATIENT INFORMATION

Avoiding Contamination of the Product

Do not touch dropper tip to any surface, as this may contaminate the contents. Do not use with contact lenses in eyes.

 

Betaxon


Betaxon Patient Information Including Side Effects

Brand Names: Betaxon

Generic Name: levobetaxolol ophthalmic (Pronunciation: lee voe bay TAX oh lol)

 

  • What is levobetaxolol ophthalmic (Betaxon)?
  • What are the possible side effects of levobetaxolol ophthalmic (Betaxon)?
  • What is the most important information I should know about levobetaxolol ophthalmic (Betaxon)?
  • What should I discuss with my healthcare provider before using levobetaxolol ophthalmic (Betaxon)?
  • How should I use levobetaxolol ophthalmic (Betaxon)?
  • What happens if I miss a dose (Betaxon)?
  • What happens if I overdose (Betaxon)?
  • What should I avoid while using levobetaxolol ophthalmic (Betaxon)?
  • What other drugs will affect levobetaxolol ophthalmic (Betaxon)?
  • Where can I get more information?

 

What is levobetaxolol ophthalmic (Betaxon)?

Levobetaxolol is in a class of drugs called beta-blockers. Levobetaxolol ophthalmic reduces pressure inside the eye.

Levobetaxolol ophthalmic is used to treat glaucoma or increased pressure in the eye.

Levobetaxolol ophthalmic may also be used for purposes other than those listed in this medication guide.

What are the possible side effects of levobetaxolol ophthalmic (Betaxon)?

If you experience any of the following serious side effects, stop using levobetaxolol ophthalmic and seek emergency medical attention or contact your doctor immediately:

  • an allergic reaction (swelling of the lips, face, or tongue; difficulty breathing; closing of the throat; or hives);
  • an asthma attack (shortness of breath, wheezing); or
  • irregular, fast, or slow heartbeats or changes in blood pressure.

Other, less serious side effects may be more likely to occur. Continue to use levobetaxolol ophthalmic and talk to your doctor if you experience

  • eye burning or stinging;
  • blurred vision;
  • anxiety;
  • dizziness; or
  • upset stomach.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

What is the most important information I should know about levobetaxolol ophthalmic (Betaxon)?

Do not touch the dropper to any surface, including the eyes or hands. The dropper is sterile. If it becomes contaminated, it could cause an infection in the eye.

Apply light pressure to the inside corner of the eye (near the nose) after each drop to prevent the fluid from draining down the tear duct.

Related Drug Centers
  • Betaxon

Betaxon


Betaxon Patient Information including How Should I Take

In this Article

  • What is levobetaxolol ophthalmic (Betaxon)?
  • What are the possible side effects of levobetaxolol ophthalmic (Betaxon)?
  • What is the most important information I should know about levobetaxolol ophthalmic (Betaxon)?
  • What should I discuss with my healthcare provider before using levobetaxolol ophthalmic (Betaxon)?
  • How should I use levobetaxolol ophthalmic (Betaxon)?
  • What happens if I miss a dose (Betaxon)?
  • What happens if I overdose (Betaxon)?
  • What should I avoid while using levobetaxolol ophthalmic (Betaxon)?
  • What other drugs will affect levobetaxolol ophthalmic (Betaxon)?
  • Where can I get more information?

What should I discuss with my healthcare provider before using levobetaxolol ophthalmic (Betaxon)?

Before using levobetaxolol ophthalmic, tell your doctor if you have

  • asthma or a chronic lung disease;
  • a very slow heart rate;
  • heart disease such as high blood pressure, heart failure, or heart block;
  • a muscle weakness disease;
  • diabetes; or
  • an overactive thyroid (hyperthyroidism).

You may not be able to use levobetaxolol ophthalmic, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.

Levobetaxolol ophthalmic is in the FDA pregnancy category C. This means that it is not known whether levobetaxolol ophthalmic will be harmful to an unborn baby. Do not use this medication without first talking to your doctor if you are pregnant or could become pregnant during treatment.

It is not known whether levobetaxolol ophthalmic passes into breast milk. Do not use levobetaxolol ophthalmic without first talking to your doctor if you are breast-feeding a baby.

How should I use levobetaxolol ophthalmic (Betaxon)?

Use levobetaxolol ophthalmic eyedrops exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Wash your hands before using the eyedrops.

If you wear contact lenses, remove them before applying levobetaxolol ophthalmic. Ask your doctor if contact lenses can be reinserted after application of the medication.

Shake the eyedrops before use.

To apply the eyedrops:

  • Tilt the head back slightly and pull down on the lower eyelid. Position the dropper above the eye. Look up and away from the dropper. Squeeze out a drop and close the eye. Apply gentle pressure to the inside corner of the eye (near the nose) for about 1 minute to prevent the liquid from draining down the tear duct. If you are using more than 1 drop in the same eye, repeat the process with about 5 minutes between drops. Repeat the process in the other eye if needed.

Do not touch the dropper to any surface, including the eyes or hands. The dropper is sterile. If it becomes contaminated, it could cause an infection in the eye.

Do not use any eyedrop that is discolored or has particles in it.

Store levobetaxolol ophthalmic at room temperature away from moisture and heat. Keep the bottle properly capped and protect it from light.

Related Drug Centers
  • Betaxon

Betaxon


Betaxon Patient Information including If I Miss a Dose

In this Article

  • What is levobetaxolol ophthalmic (Betaxon)?
  • What are the possible side effects of levobetaxolol ophthalmic (Betaxon)?
  • What is the most important information I should know about levobetaxolol ophthalmic (Betaxon)?
  • What should I discuss with my healthcare provider before using levobetaxolol ophthalmic (Betaxon)?
  • How should I use levobetaxolol ophthalmic (Betaxon)?
  • What happens if I miss a dose (Betaxon)?
  • What happens if I overdose (Betaxon)?
  • What should I avoid while using levobetaxolol ophthalmic (Betaxon)?
  • What other drugs will affect levobetaxolol ophthalmic (Betaxon)?
  • Where can I get more information?

What happens if I miss a dose (Betaxon)?

Apply the missed dose as soon as you remember. However, if it is almost time for the next regularly scheduled dose, skip the missed dose and apply the next one as directed. Do not use a double dose of this medication.

What happens if I overdose (Betaxon)?

Seek emergency medical attention if an overdose is suspected or if the drops have been ingested.

Symptoms of a levobetaxolol ophthalmic overdose may include a slow heart rate, fainting, and a heart attack.

What should I avoid while using levobetaxolol ophthalmic (Betaxon)?

Do not touch the dropper to any surface, including the eyes or hands. The dropper is sterile. If it becomes contaminated, it could cause an infection in the eye.

If you wear contact lenses, remove them before applying levobetaxolol ophthalmic. Ask your doctor if contact lenses can be reinserted after application of the medication.

Do not use other eye medications during treatment with levobetaxolol ophthalmic except under the direction of your doctor.

What other drugs will affect levobetaxolol ophthalmic (Betaxon)?

Do not use other eye medications during treatment with levobetaxolol ophthalmic except under the direction of your doctor.

Before using levobetaxolol ophthalmic, tell your doctor if you are taking any of the following drugs:

  • another beta-blocker by mouth, such as propranolol (Inderal), atenolol (Tenormin), or metoprolol (Lopressor);
  • reserpine, prazosin (Minipress), doxazosin (Cardura), tamsulosin (Flomax), or terazosin (Hytrin); or
  • a stimulant drug, such as amphetamine, amphetamine-dextroamphetamine (Adderall); dextroamphetamine (Dexedrine, Dextrostat), diethylpropion (Tenuate, Tenuate Dospan), methylphenidate (Ritalin); pemoline (Cylert); phentermine (Adipex-P, Fastin, Ionamin); and others.

You may not be able to use levobetaxolol ophthalmic, or you may require a dosage adjustment or special monitoring during treatment if you are taking any of the medicines listed above.

Drugs other than those listed here may also interact with levobetaxolol ophthalmic. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including vitamins, minerals, and herbal products.

Where can I get more information?

Your pharmacist has additional information about levobetaxolol ophthalmic written for health professionals that you may read.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2009 Cerner Multum, Inc. Version: 2.01. Revision date: 2/6/04.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Related Drug Centers
  • Betaxon
Share
 
Ruai Pharm Stats